News Novartis files CAR-T in lymphoma, sets up rivalry with Gilea... Swiss pharma to compete with Gilead in non-Hodgkin lymphoma
News Novartis adds to cancer reach with $3.9 billion acquisition Novartis backs ambition to be oncology world-leader
News Gilead gains CAR-T approval, undercuts rival's headline pric... Cancer cell therapy approved for aggressive blood cancer
News Novartis joins with Berkeley to tackle "undruggable" targets Project will focus on areas such as cancer and infectious diseases
News NICE recommends Bayer drug for severe short-sightedness Eylea should be funded in mCNV, says NICE
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.